Caleb brings more than 15 years of experience spanning biotechnology, regenerative medicine, culinary and venture creation. He was a founding scientist and early executive at Bell Biosystems, a Stanford spinout pioneering MRI-traceable cell therapies, where he helped develop novel bioengineered platforms to track and restore tissue function in vivo. He later played key leadership roles in IVIVA Medical, a Harvard-born regenerative medicine company developing bioengineered organs and tissues, which was successfully acquired by United Therapeutics.

In addition to his role at Kanjin, Caleb continues to support global innovation ecosystems, helping bridge science and entrepreneurship across Japan, the United States, and the Middle East. He works with venture groups, accelerators, and research institutions to advance cross-border collaboration and enable founders to bring transformative technologies to market.  As a venture investor, he has helped build and fund more than 30 deep-tech companies, contributing to multiple exits and unicorn outcomes.

Caleb earned his BS in Biochemistry and Molecular Biology from Pennsylvania State University and his PhD in Biophysical Chemistry from Stanford University, where he also attended the Graduate School of Business. He is the inventor on 20+ issued patents and author of 25+ peer-reviewed publications. His current work focuses on the clinical realization of living medicines, AI integration and bio-inspired innovation.